Sleep & Seizure Disorders
At PsychoGenics, we provide expert preclinical epilepsy and seizure disorder studies and services to help you discover your breakthrough therapy. Our...
Characterization of the Ube3a Mouse Model of Angelman Syndrome
Angelman Syndrome (AS) is a rare genetic neurodevelopmental disorder characterized, in part, by developmental delays, movement impairments, and difficulties with communication and language, the effects of which impact children and adults living with AS along with their caregivers. AS is most frequently caused by deletion or mutation of the Ube3a gene on the maternal allele. PsychoGenics has characterized the Ube3a mouse model of AS in both neonatal and adult mice.
Elevation of brain magnesium with Swiss chard and buckwheat extracts in an animal model of reduced magnesium dietary intake
Bassem F. El-Khodor, Karma James, Qing Chang, Wei Zhang, Yvette R. Loiselle, Chinmayee Panda & Taleen Hanania Nutritional Neuroscience. 2022...
Preclinical Tuberous Sclerosis Complex (TSC) studies
Tuberous sclerosis complex (TSC) is a rare genetic disorder that affects multiple organs, including the brain, leading to the formation...
Preclinical Rare CNS Disorders Research
PsychoGenics offers specialized preclinical research services tailored to rare CNS disorders to drive your program forward. Leveraging our translational research...
About
PsychoGenics is the only CNS-focused contract research organization (CRO) of scale. We design and execute preclinical drug discovery and early...
PhenoCube® In Vivo AI Platform for Disease Model Phenotyping
Comprehensive Phenotypic Assessment of Disease Models PhenoCube® is an innovative platform where mice are observed continuously, day and night, allowing...
Characterization of a Mouse and Rat Model of CMT1A
The below data was made possible by CMTA, the Charcot-Marie-Tooth Association. Charcot-Marie Tooth (CMT) disorders are a family of related disorders...
Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex
Theilmann, et. al, Neuropharmacology. 2020 Theilmann, W, Gericke, B,Schidlitzki, A, Anjum, S, Borsdorf, S, Harries, T, Roberds, S.L.,Aguiar, D, Brunner,...
Home
Learn about PsychoGenics’ Capabilities and Disease Models Key Therapeutic Areas Our customized preclinical testing services and industry-leading models cover a...